GlassScriptPhysician profile
David Hani Ayad
NPI 1710337829
$8,549.93
in general payments reported to CMS, 2019-2025
10 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.15 · 2023: $291 · 2024: $7,994 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,063 · Food and Beverage: $1,272 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,063.30 |
| Food and Beverage | $1,271.99 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,283.09 | 2024 | Onyx Frontier, Ffrangio |
| Boston Scientific Corporation | $1,677.76 | 2021-2025 | Avvigo Guidance System, Synergy, Wolverine Coronary Cutting Balloon |
| Philips North America LLC | $174.41 | 2021-2024 | (Bq9) Coronary Ivus |
| Penumbra, INC. | $141.22 | 2024 | Indigo System |
| Shockwave Medical, INC | $71.98 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Chiesi USA, INC. | $70.29 | 2024 | Kengreal |
| Pfizer INC. | $43.46 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.88 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $31.05 | 2023 | Sapien 3 Ultra Resilia |
| Spectrawave, INC | $13.79 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.